Written Question · S2W-31833 · Session 2
Whether Coproxamol will continue to be obtainable on prescription in Scotland.
The question
To ask the Scottish Executive whether Coproxamol will continue to be obtainable on prescription in Scotland.
The answer
Licensing of medicines is reservedand is the responsibility of the Medicines and Healthcare products Regulatory Agency.
The agency has advised that Coproxamolis being phased out of the market gradually to give patients time to discuss theirtreatment with their doctor and change to a suitable alternative. Continued provision of Coproxamol through normal prescribingmay continue until the cancellation of the licences at the end of 2007. Followingcancellation of the licences there will be scope for the prescription of unlicensedco-proxamol. There is clear provision in legislation which gives the right to theprescriber to prescribe off-label or unlicensed medicines when this is judged tobe in the best interests of the patient.
So where there is a clear clinicalneed, it will still be possible to prescribe Coproxamol but in a way that is moretargeted, with a stronger focus on the risk:benefit judgment for the particularpatient, and involvement of the patient in the decision.
The agency has advised that Coproxamolis being phased out of the market gradually to give patients time to discuss theirtreatment with their doctor and change to a suitable alternative. Continued provision of Coproxamol through normal prescribingmay continue until the cancellation of the licences at the end of 2007. Followingcancellation of the licences there will be scope for the prescription of unlicensedco-proxamol. There is clear provision in legislation which gives the right to theprescriber to prescribe off-label or unlicensed medicines when this is judged tobe in the best interests of the patient.
So where there is a clear clinicalneed, it will still be possible to prescribe Coproxamol but in a way that is moretargeted, with a stronger focus on the risk:benefit judgment for the particularpatient, and involvement of the patient in the decision.
In the Official Report
No contribution in the Official Report cites S2W-31833 by reference.